검색
Leap Therapeutics Inc
LPTX관심 목록에 추가
2.050USD
0.0000.00%
종가 05/15, 16:00（ET）시세는 15분 지연됩니다
115.51M시가총액
손실P/E TTM
자세한 내용은 Leap Therapeutics Inc 회사
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Leap Therapeutics Inc 정보
종목 코드 LPTX
회사 이름Cypherpunk Technologies Inc
상장일Jan 24, 2017
CEOOnsi (Douglas E)
직원 수52
유형Ordinary Share
회계 연도 종료Jan 24
주소47 Thorndike Street
도시CAMBRIDGE
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호02142
전화16172524343
웹사이트https://www.leaptx.com/
종목 코드 LPTX
상장일Jan 24, 2017
CEOOnsi (Douglas E)
Leap Therapeutics Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
168.96K
+99.87%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
168.75K
--
Mr. Nissim Mashiach
Mr. Nissim Mashiach
Independent Director
Independent Director
168.75K
--
Mr. Christian M. Richard
Mr. Christian M. Richard
Independent Director
Independent Director
168.75K
--
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+0.50%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
132.51K
+82.07%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
--
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
--
Dr. Thomas Dietz, Ph.D.
Dr. Thomas Dietz, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
168.96K
+99.87%
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
168.75K
--
Mr. Nissim Mashiach
Mr. Nissim Mashiach
Independent Director
Independent Director
168.75K
--
Mr. Christian M. Richard
Mr. Christian M. Richard
Independent Director
Independent Director
168.75K
--
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+0.50%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
132.51K
+82.07%
수익 분석
기업이 아직 관련 데이터를 공개하지 않았습니다.
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
기업이 아직 관련 데이터를 공개하지 않았습니다.
주식 보유 통계
마지막 업데이트: Sun, May 10
마지막 업데이트: Sun, May 10
주주
주주 유형
주주
주주
비율
Winklevoss Capital Management, LLC
8.48%
Severns (Sean Michael)
6.14%
BlackRock Institutional Trust Company, N.A.
2.40%
Simplify Asset Management Inc
1.92%
Vanguard Capital Management, LLC
1.86%
기타
79.20%
주주
주주
비율
Winklevoss Capital Management, LLC
8.48%
Severns (Sean Michael)
6.14%
BlackRock Institutional Trust Company, N.A.
2.40%
Simplify Asset Management Inc
1.92%
Vanguard Capital Management, LLC
1.86%
기타
79.20%
주주 유형
주주
비율
Family Office
8.48%
Individual Investor
8.02%
Investment Advisor
7.81%
Corporation
1.24%
Investment Advisor/Hedge Fund
0.81%
Venture Capital
0.69%
Research Firm
0.33%
Hedge Fund
0.18%
기타
72.42%
기관 주식 보유
마지막 업데이트: Wed, Apr 1
마지막 업데이트: Wed, Apr 1
보고 기간
기관 수
보유 주식
비율
변동
2026Q1
114
11.73M
12.01%
-9.05M
2025Q4
110
8.00M
14.12%
-12.05M
2025Q3
109
9.06M
16.46%
-11.77M
2025Q2
120
18.70M
45.12%
-8.55M
2025Q1
140
18.85M
45.62%
-6.95M
2024Q4
134
21.35M
55.72%
-2.16M
2024Q3
140
20.83M
54.42%
+2.16M
2024Q2
141
20.87M
54.74%
+4.28M
2024Q1
149
9.36M
39.74%
-1.79M
2023Q4
154
7.72M
34.00%
-3.79M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Winklevoss Capital Management, LLC
8.28M
9.21%
+8.28M
--
Oct 24, 2025
Severns (Sean Michael)
6.00M
6.67%
+6.00M
--
Nov 12, 2025
BlackRock Institutional Trust Company, N.A.
2.34M
2.6%
+2.22M
+1770.24%
Dec 31, 2025
Simplify Asset Management Inc
1.87M
2.08%
+896.71K
+91.91%
Dec 31, 2025
Beigene Ltd
1.22M
1.35%
+1.22M
--
Oct 31, 2024
HealthCare Ventures LLC
676.32K
0.75%
-20.91K
-3.00%
Oct 24, 2025
Susquehanna International Group, LLP
557.18K
0.62%
+470.98K
+546.41%
Dec 31, 2025
Geode Capital Management, L.L.C.
530.19K
0.59%
+218.00K
+69.83%
Dec 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
Simplify Health Care ETF
0.37%
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Avantis US Small Cap Equity ETF
0%
Simplify Health Care ETF
비율0.37%
iShares Micro-Cap ETF
비율0%
Dimensional US Core Equity 1 ETF
비율0%
DFA Dimensional US Sustainability Core 1 ETF
비율0%
Avantis US Small Cap Equity ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
날짜
배당락일
유형
비율
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
